new monetary system- Top searches

The Taiwan Affairs Office of the State Council introduced the annual meeting of the 2024 Cross-Strait Entrepreneur Summit. Zhu Fenglian, a spokesperson for the Taiwan Affairs Office, said that the 2024 Cross-Strait Entrepreneur Summit was successfully held in Xiamen, Fujian from December 9 to 10. More than 700 business people from both sides of the Taiwan Strait attended the annual summit. Focusing on the theme of "Building a new era industrial chain across the Taiwan Strait to promote cross-strait economic integration and development", they conducted in-depth discussions on issues such as promoting cross-strait industrial Internet innovation, building Taiwanese enterprises to land in their first homes, and innovating cross-strait financial service systems. The exchange atmosphere was warm, which fully demonstrated the common aspiration of cross-strait industries to strengthen exchanges and cooperation. (Riyue Tan Tian)On the 11th, the 10-year treasury bond futures fell by 0.09%, and the latest main contract positions changed as follows. According to the exchange data, as of December 11th, the main contract 10-year treasury bond futures closed at 2503, up or down by -0.09%, with a turnover of 65,600 lots. The position data showed that the top 20 seats were clear, and the difference position was 4,068 lots. The total number of 10-year treasury bond futures contracts was 69,300 lots, a decrease of 26,600 lots from the previous day. The first 20 seats in the contract held 176,000 lots, a decrease of 3,678 lots from the previous day. The short positions in the top 20 seats of the contract were 181,200 lots, a decrease of 713 lots from the previous day. (Sina Futures)Kyle Rodda, a financial market analyst in Capital.com, looks forward to the US CPI in November: The expected CPI data basically gives the Fed a green light to cut interest rates next week, which may be the gold catalyst we need to see.

Modern Pharmaceuticals: Sinopharm Zhijun, the holding subsidiary, obtained the drug registration certificate of Cefotaxime Tablets. Modern Pharmaceuticals announced that Sinopharm Zhijun Pharmaceutical Co., Ltd., the holding subsidiary, recently received the Drug Registration Certificate of Cefotaxime Tablets approved and issued by National Medical Products Administration. Cefopoxime axetil tablets are the third generation cephalosporins taken orally, which are used to treat upper respiratory tract infections and lower respiratory tract infections caused by sensitive bacteria. In 2023, the global sales of preparations will be USD 370 million, and the sales of public hospitals nationwide will be RMB 102 million. The accumulative R&D investment of Sinopharm Zhijun is about RMB 28.45 million. Obtaining the registration certificate will enrich the company's product line, increase market competitiveness and have a positive impact on the company's future development. However, drug sales are easily affected by factors such as policies and market environment, and there are uncertainties.South Korea's opposition parties condemned Yin Xiyue's office for preventing the police from searching.The price of basic load electricity delivered in France the next day rose by 12.8% to 190 euros/megawatt hour.

Market News: The Ukrainian military said that the attack on the Russian oil depot triggered a "fire".Comments on Hong Kong stocks: Hang Seng Index fell by 0.77%, Hang Seng Technology Index fell by 1.31%, Hong Kong stocks closed, Hang Seng Technology Index fell by 0.77%, Hang Seng Technology Index fell by 1.31%, dropped by over 5%, and JD.COM Group and Meituan fell by over 2%.Bank of America: restore coverage to AbbVie, give it a "neutral" rating, and target price is $191.